Gapping down
Other news:
- ICPT -38.1% (announces the FDA issued a Complete Response Letter regarding the New Drug Application for obeticholic acid for the treatment of fibrosis due to nonalcoholic steatohepatitis)
- GNUS -6.5% (files for 59,523,812 share common stock offering by selling shareholders)
- DRRX -5.7% (announces that Gilead is terminating its license agreement related to an HIV investigational product using DURECT's SABER technology)
- FB -3.3% (social media names continue to show weakness after more corporations boycot ads)
- CACC -2.7% (received another civil investigative demand on June 1)
- SNAP -2.5% (social media names continue to show weakness after more corporations boycot ads)
- TWTR -2.4% (social media names continue to show weakness after more corporations boycot ads)
- TAK -1.2% (announces anticipated financial impact from Novartis' (NVS) withdrawal of the Marketing Authorisation Application for Xiidra)
- VERU -0.9% (files for $150 mln mixed securities shelf offering)
Analyst comments:
- AMC -4.5% (downgraded to Underperform from Neutral at Credit Suisse)
- ALGT -2.5% (downgraded to Neutral from Buy at Goldman)
- SPOT -2.1% (downgraded to Sell from Neutral at Guggenheim)
- BYND -2% (downgraded to Underweight from Overweight at Barclays)
- CNK -1.5% (downgraded to Neutral from Outperform at Credit Suisse)
- UL -1.1% (downgraded to Sell from Neutral at UBS)
- PPC -0.8% (downgraded to Market Perform from Outperform at BMO Capital Markets)